• Chronic obstructive pulmonary disease (COPD):
    • 5mL nebulized QID OR 1 dose inhaled QID
      • Max 6 doses/24 hrs.
  • Moderate-severe exacerbation of asthma (Off-label):
    • Adults:5mL nebulised every 20min *3 doses, then PRN up to 3 hours
    • Children <13 years: 1-2.5mL nebulised every 20min *3 doses, then PRN up to 3 hours
  • Nebulising solution:
    • 5mg/3mg per 2.5mL
    • 5mg/1.25mg per 2.5mL
  • Inhaler:
    • 20mcg/100mcg
    • 120mcg/21mcg

Inhaler:

  • Actuate before use by pumping 2 puffs in the air before use.
  • Prime inhaler again if not used for >7 days
  • Rinse mouth with water after use.

 

 

Ipratropium: Anticholinergic agent. It prevents increase in intracellular calcium concentration caused by interaction of acetylcholine with muscarinic receptors on bronchial smooth muscle causing bronchodilation

Salbutamol: Beta-2-adrenergic bronchodilator. It selectively stimulates beta-2 adrenergic receptors, relaxing airway smooth muscle.

  • Pharyngitis
  • Chest pain
  • Hyperlactatemia
  • Bronchitis
  • Hypersensitivity to drug or ingredient
  • Hypersensitivity to atropine
  • Children <12 years
  • Hypertrophic obstructive cardiomyopathy
  • Tachyarrhythmia
  • Cisapride
  • Dronedarone
  • Saquinavir
  • Thioridazine

                                   Drug Status

Availability Prescription only
Pregnancy Can be used
Breastfeeding Can be used
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Combivent 0.5mg/3mg per 2.5mL Nebuliser Solution 20’s Boehringer Ingelheim Surgipharm Ltd
Combivent 120mcg/21mcg Inhalation 200D Boehringer Ingelheim Surgipharm Ltd
Dulocip 20mcg/100mcg Inhalation 200D Cipla Ltd Imperial Managed
Dulocip Respules 5mg/1.25mg per 2.5mL Nebuliser Solution 20’s Cipla Ltd Imperial Managed